GSK-3β inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes

This publication has 48 references indexed in Scilit:

• Expression and activity of C/EBPβ and δ are upregulated by dexamethasone in skeletal muscle
  Journal of Cellular Physiology, 2005
• Treatment of cultured myotubes with the calcium ionophore A23187 increases proteasome activity via a CaMK II-caspase-calpain–dependent mechanism
  Surgery, 2004
• The IGF-1/PI3K/Akt Pathway Prevents Expression of Muscle Atrophy-Induced Ubiquitin Ligases by Inhibiting FOXO Transcription Factors
  Molecular Cell, 2004
• Lithium Stabilizes the CCAAT/Enhancer-binding Protein α (C/EBPα) through a Glycogen Synthase Kinase 3 (GSK3)-independent Pathway Involving Direct Inhibition of Proteasomal Activity
  Published by Elsevier ,2003
• The multifaceted roles of glycogen synthase kinase 3β in cellular signaling
  Published by Elsevier ,2001
• Lithium Inhibits Glycogen Synthase Kinase-3 by Competition for Magnesium
  Biochemical and Biophysical Research Communications, 2001
• Specificity and mechanism of action of some commonly used protein kinase inhibitors
  Biochemical Journal, 2000
• Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
  Nature, 1995
• Sepsis stimulates nonlysosomal, energy-dependent proteolysis and increases ubiquitin mRNA levels in rat skeletal muscle.
  Journal of Clinical Investigation, 1994
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
  Analytical Biochemistry, 1976